Literature DB >> 25234407

Statins are associated with low risk of venous thromboembolism in patients with cancer: a prospective and observational cohort study.

Felix Lötsch1, Oliver Königsbrügge1, Florian Posch1, Christoph Zielinski2, Ingrid Pabinger1, Cihan Ay3.   

Abstract

INTRODUCTION: Patients with cancer are at risk of venous thromboembolism (VTE). Statin-use has been shown to be associated with low risk of VTE in patients without cancer, but data in cancer patients is scarce. The objective of this study was to evaluate the association of statins with risk of VTE in cancer patients in a prospective observational cohort study.
MATERIALS AND METHODS: Patients with newly diagnosed cancer or progression of disease after remission were included and prospectively followed for a maximum of 2 years. Study endpoint was occurrence of symptomatic VTE.
RESULTS: Patients (n=1434) were followed over a median observation period of 729 days. VTE occurred in 107 (7.5%) patients. At study inclusion, 170 (11.9%) patients took statins. Simvastatin (n=96) and atorvastatin (n=48) were the most frequently prescribed statins. VTE occurred in 6 (3.5%) patients with statins. Patients with statins had a lower risk of VTE than patients without (subhazard ratio 0.43, 95% confidence interval 0.19 to 0.98; p=0.04). In competing risk analysis, the cumulative probability of VTE in patients with statins was 2.94% after 12 months and 3.54% after 24 months, compared to 7.13% and 8.13% in the group without statins (Gray's test: p=0.04).
CONCLUSION: This study provides observational evidence for an association between statin use and low risk of VTE in patients with cancer. The role of statins for prevention of cancer-associated VTE needs to be confirmed in randomized, controlled trials.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Neoplasms; Simvastatin; Statins; Thrombosis; Venous thromboembolism

Mesh:

Substances:

Year:  2014        PMID: 25234407     DOI: 10.1016/j.thromres.2014.09.001

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  10 in total

Review 1.  Venous thrombosis and cancer: from mouse models to clinical trials.

Authors:  Y Hisada; J E Geddings; C Ay; N Mackman
Journal:  J Thromb Haemost       Date:  2015-06-26       Impact factor: 5.824

2.  Statin Use and Survival in Resectable Pancreatic Cancer: Confounders and Mechanisms.

Authors:  Livia Archibugi; Gabriele Capurso; Gianfranco Delle Fave
Journal:  Am J Gastroenterol       Date:  2016-03       Impact factor: 10.864

3.  Statin use and venous thromboembolism in cancer: A large, active comparator, propensity score matched cohort study.

Authors:  Sherif M El-Refai; Esther P Black; Val R Adams; Jeffery C Talbert; Joshua D Brown
Journal:  Thromb Res       Date:  2017-08-10       Impact factor: 3.944

4.  Epidemiologic Analysis Along the Mevalonate Pathway Reveals Improved Cancer Survival in Patients Who Receive Statins Alone and in Combination With Bisphosphonates.

Authors:  Sherif M El-Refai; Joshua D Brown; Susanne M Arnold; Esther P Black; Markos Leggas; Jeffery C Talbert
Journal:  JCO Clin Cancer Inform       Date:  2017-11

Review 5.  Statins as a preventative therapy for venous thromboembolism.

Authors:  Alex Wallace; Hassan Albadawi; Peter Hoang; Andrew Fleck; Sailendra Naidu; Grace Knuttinen; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

Review 6.  Pleiotropic effects of statins in the diseases of the liver.

Authors:  Martin Janicko; Sylvia Drazilova; Daniel Pella; Jan Fedacko; Peter Jarcuska
Journal:  World J Gastroenterol       Date:  2016-07-21       Impact factor: 5.742

7.  Ex vivo properties of plasma clot formation and lysis in patients with cancer at risk for venous thromboembolism, arterial thrombosis, and death.

Authors:  Florian Posch; Stefanie Hofer; Johannes Thaler; Lena Hell; Oliver Königsbrügge; Ella Grilz; Lisa-Marie Mauracher; Johanna Gebhart; Christine Marosi; Bernd Jilma; Ingrid Pabinger; Cihan Ay
Journal:  Transl Res       Date:  2019-08-29       Impact factor: 7.012

8.  Lovastatin Decreases the Expression of CD133 and Influences the Differentiation Potential of Human Embryonic Stem Cells.

Authors:  Ade Kallas-Kivi; Annika Trei; Toivo Maimets
Journal:  Stem Cells Int       Date:  2016-05-10       Impact factor: 5.443

Review 9.  From Classical Laboratory Parameters to Novel Biomarkers for the Diagnosis of Venous Thrombosis.

Authors:  Larisa Anghel; Radu Sascău; Rodica Radu; Cristian Stătescu
Journal:  Int J Mol Sci       Date:  2020-03-11       Impact factor: 5.923

10.  Effect of Statins on Survival Following Stroke in Patients With Cancer.

Authors:  Ye Sel Kim; Moo-Seok Park; Jun-Hwa Lee; Jong-Won Chung; Mi Ji Lee; Chi Kyung Kim; Jin-Man Jung; Kyungmi Oh; Oh Young Bang; Geong-Moon Kim; Ji-Mi Choi; Juneyoung Lee; Chin Sang Chung; Kwang Ho Lee; Woo-Keun Seo
Journal:  Front Neurol       Date:  2018-04-24       Impact factor: 4.003

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.